HONG KONG – South Korean drugmaker Celltrion Inc. has received marketing approval for its star product, Remsima, an infliximab biosimilar, in Brazil and Venezuela, marking the beginning of the company's expansion into Latin America.
HONG KONG – Taigen Biotechnology Co. Ltd. started the first clinical trials of its stem cell mobilizer drug, burixafor (TG-0054), in mainland China. It received regulatory clinical trial approval from the CFDA in 2013 for phase I and II trials as a chemotherapy sensitizer in combination with two chemotherapeutic agents for the treatment of leukemia.
HONG KONG – Wuxi Pharmatech Inc. is building a $150 million biologics manufacturing facility for subsidiary Wuxi Biologics – the largest of its kind in China. When finished, the new facility will put the company in a different league, multiplying its production capacity and doubling its client base.
HONG KONG – Wuxi Pharmatech Inc. is building a $150 million biologics manufacturing facility for subsidiary Wuxi Biologics – the largest of its kind in China. When finished, the new facility will put the company in a different league, multiplying its production capacity and doubling its client base.
HONG KONG – A new patent law could help China step up enforcement and improve protections for intellectual property while giving biotech companies, both multinational and domestic, greater assurances that their products will be protected.
HONG KONG – A new patent law could help China step up enforcement and improve protections for intellectual property while giving biotech companies, both multinational and domestic, greater assurances that their products will be protected.
